Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Core Viewpoint - Propanc Biopharma, Inc. is pursuing a strategic initiative to acquire undervalued Digital Asset Treasury (DAT) companies that are trading below their Market Cap to Net Asset Value (MNAV) [1][2]. Group 1: Acquisition Strategy - The management believes that acquiring undervalued DAT entities will strengthen the company's balance sheet, diversify its asset base, and create long-term shareholder value [2][4]. - DAT companies typically hold significant reserves of leading digital assets such as Bitcoin (BTC) and Ethereum (ETH) [2]. Group 2: Market Context - The total value held by Bitcoin Treasury companies is approximately $76.9 billion, while Ethereum-based DATs hold about $17.6 billion in digital assets [3]. - Many DAT entities are trading at substantial discounts to their net asset values, presenting a unique opportunity for acquisitions [3]. Group 3: Management's Perspective - CEO James Nathanielsz stated that this initiative is a strategic diversification effort aimed at unlocking value for shareholders [4]. - The company is currently evaluating potential acquisition targets and developing due diligence frameworks to assess balance sheet strength, digital asset holdings, and operational synergies [4][5].